Peijia Medical Gestione

Gestione criteri di controllo 3/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Yi Zhang

Amministratore delegato

CN¥1.5m

Compenso totale

Percentuale dello stipendio del CEO	50.7%
Mandato del CEO	12.5yrs
Proprietà del CEO	0.8%
Durata media del management	5.1yrs
Durata media del Consiglio di amministrazione	5yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Yi Zhang rispetto agli utili di Peijia Medical?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-CN¥252m
Mar 31 2024	n/a	n/a	-CN¥322m
Dec 31 2023	CN¥1m	CN¥740k	-CN¥393m
Sep 30 2023	n/a	n/a	-CN¥460m
Jun 30 2023	n/a	n/a	-CN¥528m
Mar 31 2023	n/a	n/a	-CN¥468m
Dec 31 2022	CN¥1m	CN¥1m	-CN¥408m
Sep 30 2022	n/a	n/a	-CN¥449m
Jun 30 2022	n/a	n/a	-CN¥491m
Mar 31 2022	n/a	n/a	-CN¥533m
Dec 31 2021	CN¥2m	CN¥1m	-CN¥574m

Compensazione vs Mercato: La retribuzione totale di Yi ($USD 201.50K ) è inferiore alla media delle aziende di dimensioni simili nel mercato German ($USD 1.03M ).

Compensazione vs guadagni: La retribuzione di Yi è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Yi Zhang (56 yo)

12.5yrs

Mandato

CN¥1,460,000

Compensazione

Dr. Yi Zhang has been an Executive Director of Peijia Medical Limited since May 30, 2012. He serves as the Chairman and Chief Executive Officer at Peijia Medical Limited and served as its Chief Technology...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Yi Zhang	Chairman & CEO	no data	CN¥1.46m	0.80% € 2.4m
Lieh Tsai	Chief Financial Officer	5.6yrs	Nessun dato	Nessun dato
Kongrong Pan	Chief Operating Officer	7.3yrs	Nessun dato	Nessun dato
Fong Tan Jian	Chief Technology Officer	3.8yrs	Nessun dato	Nessun dato
Ping Ye Zhang	Executive Director	4.8yrs	CN¥182.00k	0.16% € 464.3k
Hong Ye	Executive Director & Company Secretary	12.1yrs	CN¥1.36m	2.09% € 6.2m
Xiaoxiao Zhuang	Vice President of Sales	4.6yrs	Nessun dato	Nessun dato
Hongpeng Wang	Vice President of Marketing	5.3yrs	Nessun dato	Nessun dato
Hing Ling Chau	Company Secretary	2.4yrs	Nessun dato	Nessun dato

5.1yrs

Durata media

49yo

Età media

Gestione esperta: Il team dirigenziale di 4WO è esperto e expertise (durata media dell'incarico 5.1 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Yi Zhang	Chairman & CEO	12.5yrs	CN¥1.46m	0.80% € 2.4m
Ping Ye Zhang	Executive Director	6.3yrs	CN¥182.00k	0.16% € 464.3k
Hong Ye	Executive Director & Company Secretary	12.1yrs	CN¥1.36m	2.09% € 6.2m
Stephen Newman Oesterle	Independent Non-Executive Director	4.8yrs	CN¥1.55m	Nessun dato
Huacheng Wei	Independent Non-Executive Director	3.2yrs	CN¥315.00k	Nessun dato
Wai Ming Yip	Independent Non-Executive Director	4.8yrs	CN¥314.00k	Nessun dato
Fei Chen	Non-Executive Director	5.4yrs	Nessun dato	Nessun dato
Robert Parks	Independent Non-Executive Director	4.8yrs	CN¥1.55m	Nessun dato
Jifeng Guan	Non-Executive Director	5.1yrs	Nessun dato	Nessun dato
Jun Yang	Non-Executive Director	4.3yrs	Nessun dato	Nessun dato

5.0yrs

Durata media

56yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 4WO sono considerati esperti (durata media dell'incarico 5 anni).

Peijia Medical Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Peijia Medical Limited Announces Resignation of Yu Zhiyun as Non-Executive Director and A Member of the Board's Remuneration Committee

Less than half of directors are independent

Peijia Medical Limited, Annual General Meeting, Sep 30, 2024

Less than half of directors are independent

Executive Director & Company Secretary recently sold €362k worth of stock

Less than half of directors are independent

Recent updates

Peijia Medical Limited Announces Resignation of Yu Zhiyun as Non-Executive Director and A Member of the Board's Remuneration Committee

First half 2024 earnings released: CN¥0.10 loss per share (vs CN¥0.31 loss in 1H 2023)

Less than half of directors are independent

Peijia Medical Limited, Annual General Meeting, Sep 30, 2024

Peijia Medical Limited to Report First Half, 2024 Results on Aug 23, 2024

Peijia Medical Limited to Report Fiscal Year 2023 Results on Jun 15, 2024

Peijia Medical Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Peijia Medical Announces Successful Completion of Patient Enrollment for Pivotal TaurusTrio Transcatheter Aortic Regurgitation Clinical Trial

First half 2023 earnings released: CN¥0.31 loss per share (vs CN¥0.14 loss in 1H 2022)

Less than half of directors are independent

Forecast to breakeven in 2025

First half 2023 earnings released: CN¥0.31 loss per share (vs CN¥0.14 loss in 1H 2022)

New major risk - Share price stability

Peijia Medical Limited to Report First Half, 2023 Results on Aug 31, 2023

Peijia Medical Limited Announces First Patient in Multi-Center Registration Clinical Trial of Taurustrio™? Transcatheter Aortic Valve Replacement System in China

Peijia Medical Limited Provides Unaudited Revenue Guidance for the Period from January 1, 2023 to June 30, 2023

New minor risk - Profitability

Peijia Medical Limited Receives Approval from the National Medical Products Administration of the PRC for the Registration Application of DCwireTM Micro Guidewire

New minor risk - Share price stability

Executive Director & Company Secretary recently sold €362k worth of stock

Forecast to breakeven in 2025

Peijia Medical Limited Announces First Patient Enrollment in the Multi-Center Registration Clinical Trial of Geminione Transcatheter Edge-To-Edge Repair System in China

Peijia Medical Limited Announces in Partnership with inQB8 Medical Technologies, LLC Successfully Completed the First Patient Implant in the First-In-Man Clinical Trial of the MonarQ Transcatheter Tricuspid Valve Replacement System in the World

Less than half of directors are independent

Peijia Medical Limited Announces First Patient Implant in Multi-Center Registrationclinical Trial of Peijia Highlife Transcatheter Mitralvalve Replacement System in China

Less than half of directors are independent

First half 2022 earnings released: CN¥0.14 loss per share (vs CN¥0.27 loss in 1H 2021)

Peijia Medical Limited to Report First Half, 2022 Results on Aug 19, 2022

Forecast to breakeven in 2024

Peijia Medical Limited Announces Executive Changes

Peijia Medical Limited Receives NMPA Approval for Registration Application of Fluxcap Balloon Guide Catheter

Peijia Medical Limited Receives the Approval from the National Medical Products Administration of the PRC for the Registration Application of Tethys AS Aspiration Catheter

Peijia Medical Limited, Annual General Meeting, Jun 10, 2022

Full year 2021 earnings released: CN¥0.87 loss per share (vs CN¥4.43 loss in FY 2020)

Less than half of directors are independent

Full year 2021 earnings released: CN¥0.86 loss per share (vs CN¥4.43 loss in FY 2020)

Peijia Medical Limited to Report Fiscal Year 2021 Results on Mar 31, 2022

Peijia Medical Limited Receives the Approval from the National Medical Products Administration for Syphonet® Stent Retriever

Peijia Medical Limited Announces First Patient Implant in Research Clinical Trial of Peijia's Highlife Trans-Septal Mitral Valve Replacement System in China

Peijia Medical Announces First Patient Implant in the Clinical Trial of Its Third-Generation Transcatheter Aortic Valve System TaurusNXT

Peijia Medical Limited Announces First Patient Implant in Clinical Trial of TaurusNXT

First half 2021 earnings released: CN¥0.27 loss per share (vs CN¥8.68 loss in 1H 2020)

Peijia Medical Limited Receives the Approval from the National Medical Products Administration of the PRC of the Registration Application for TaurusElite

Full year 2020 earnings released: CN¥4.43 loss per share (vs CN¥2.33 loss in FY 2019)

Full year 2020 earnings released: CN¥4.43 loss per share (vs CN¥2.26 loss in FY 2019)

Peijia Medical Limited to Report Fiscal Year 2020 Results on Mar 29, 2021

Peijia Medical Limited Announces Patient Enrollment for the Clinical Trial Ofshenyi Stent Retriever

New 90-day high: €3.20

New 90-day low: €2.34

New 90-day low: €2.60

Peijia Medical Limited Announces Completion of Patient Enrollment for the Clinical Trial of Tauruselite

Peijia Medical Limited to Report First Half, 2020 Results on Aug 28, 2020

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media